• 1. Excimer–monomer switch: a reaction-based approach for selective detection of fluoride?
  Qiao Song,Angela Bamesberger,Lingyun Yang,Haley Houtwed,Haishi Cao Analyst, 2014,139, 3588-3592
• 2. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
• 3. Fe3O4/Au/Fe3O4 nanoflowers exhibiting tunable saturation magnetization and enhanced bioconjugation
  Feng Shi,Kunping Yan,Mingli Peng,Xiao Cheng,Yanling Luo,Xuemei Chen,V. A. L. Roy,Zuankai Wang Nanoscale, 2012,4, 747-751
• 4. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 5. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Pyrazole carboxylic acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Pyrazoles Pyrazole carboxylic acids and derivatives

Introduction to 5H,6H,7H-pyrazolo[3,2-b][1,3]oxazine-2-carboxylic acid (CAS No. 718621-99-9)

5H,6H,7H-pyrazolo[3,2-b][1,3]oxazine-2-carboxylic acid, identified by the Chemical Abstracts Service Number (CAS No.) 718621-99-9, is a heterocyclic compound that has garnered significant attention in the field of medicinal chemistry due to its unique structural and pharmacological properties. This compound belongs to the pyrazolo[3,2-b][1,3]oxazine class, a scaffold that has been increasingly explored for its potential in drug discovery and development. The presence of both pyrazole and oxazine rings in its structure imparts a rich chemical diversity that makes it a promising candidate for various biological applications.

The 5H,6H,7H-pyrazolo[3,2-b][1,3]oxazine-2-carboxylic acid scaffold exhibits remarkable versatility in terms of chemical modification and functionalization. This flexibility allows researchers to design derivatives with tailored biological activities, making it an attractive platform for the development of novel therapeutic agents. The carboxylic acid moiety at the 2-position of the oxazine ring provides a reactive site for further functionalization, enabling the synthesis of esters, amides, and other pharmacophores that can enhance drug-like properties such as solubility and bioavailability.

Recent advancements in computational chemistry and molecular modeling have facilitated a deeper understanding of the interactions between 5H,6H,7H-pyrazolo[3,2-b][1,3]oxazine-2-carboxylic acid and biological targets. These studies have highlighted its potential as an inhibitor of various enzymes and receptors involved in critical cellular pathways. For instance, derivatives of this compound have shown promise in inhibiting kinases associated with cancer progression. The ability to modulate these pathways makes 5H,6H,7H-pyrazolo[3,2-b][1,3]oxazine-2-carboxylic acid a valuable asset in the quest for targeted therapies.

In addition to its kinase inhibition properties, research has also explored the antimicrobial and anti-inflammatory potential of 5H,6H,7H-pyrazolo[3,2-b][1,3]oxazine-2-carboxylic acid. The structural features of this compound contribute to its ability to disrupt microbial cell membranes and inhibit inflammatory responses. These findings are particularly relevant in the context of rising antibiotic resistance and chronic inflammatory diseases. The compound's dual functionality as both an antimicrobial agent and an anti-inflammatory modulator positions it as a multifaceted therapeutic option.

The synthesis of 5H,6H,7H-pyrazolo[3,2-b][1,3]oxazine-2-carboxylic acid involves multi-step organic reactions that require precise control over reaction conditions to ensure high yield and purity. Advanced synthetic methodologies have been employed to optimize these processes. For example, transition metal-catalyzed cross-coupling reactions have been utilized to construct the pyrazole and oxazine rings efficiently. These techniques not only improve synthetic efficiency but also allow for greater customization of the final product.

One of the most compelling aspects of 5H,6H,7H-pyrazolo[3,2-b][1,3]oxazine-2-carboxylic acid is its potential for further derivatization to enhance pharmacological activity. By introducing various substituents at different positions on the scaffold? researchers can fine-tune its biological effects. For instance， modifications at the 5-position of the pyrazole ring can influence binding affinity to target proteins while changes at the 4-position of the oxazine ring can modulate metabolic stability. Such structural diversification is key to developing compounds with improved pharmacokinetic profiles.

The pharmacokinetic properties of 5H，6H，7H-pyrazolo[3，2-b][1，3]oxazine-2-carboxylic acid derivatives are also subjects of intense investigation。 Studies have demonstrated that certain modifications can enhance oral bioavailability by improving solubility and reducing metabolic degradation。 Additionally， advances in prodrug design have allowed for the development of formulations that release active compounds in a controlled manner， thereby prolonging their therapeutic effect。

Preclinical studies have provided valuable insights into the safety и efficacy profiles c?a các derivatives c?a 5H，6H，7H-pyrazolo[3，2-b][1，3]oxazine-2-carboxylic acid。 These investigations have revealed that certain analogs exhibit low toxicity при high doses и demonstrate significant therapeutic benefits in animal models of human diseases。 Such findings are crucial steps toward translating laboratory discoveries into clinical applications。

The future direction c?a research on 5H，6H，7H-pyrazolo[3，2-b][1，3]oxazine-2-carboxylic acid is likely to focus on expanding its therapeutic applications。 Efforts are underway to explore its potential in treating neurological disorders? metabolic diseases? và infectious diseases。 The versatility c?a this scaffold makes it an ideal candidate for developing next-generation therapeutics that address unmet medical needs。

In conclusion， 5H，6H，7H-pyrazolo[3，2-b][1，3]oxazine-2-carboxylic acid (CAS No. 718621-99-9) represents a promising area of investigation in medicinal chemistry。 Its unique structure? synthetic accessibility? và diverse biological activities make it a valuable scaffold for drug discovery。 As research continues to uncover new applications và optimize synthetic methodologies? this compound is poised to play a significant role in future pharmaceutical developments。

• 1707365-33-0(Spiro[5,7-dihydropyrazolo[5,1-b][1,3]oxazine-6,1'-cyclobutane]-2-carboxylic acid)
• 1263211-61-5(5-Methoxy-1-(2-methoxyethyl)-1H-pyrazole-3-carboxylic acid)
• 1265895-04-2(2-((6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-2-yl)methoxy)acetic acid)
• 1239722-75-8(2H,3H-pyrazolo[3,2-b][1,3]oxazole-6-carboxylic acid)
• 1239844-59-7(3-methyl-5H,6H,7H-pyrazolo3,2-b1,3oxazine-2-carboxylic acid)
• 623565-63-9(5H,6H,7H-pyrazolo[3,2-b][1,3]oxazine-2-carbaldehyde)
• 623565-62-8({5H,6H,7H-pyrazolo[3,2-b][1,3]oxazin-2-yl}methanol)
• 1428234-37-0(spiro[cyclopropane-1,6'-pyrazolo[5,1-b][1,3]oxazine]-2'-carboxylic acid)
• 623565-48-0(Ethyl 2,3-Dihydropyrazolo5,1-b1,3oxazole-6-carboxylate)
• 153597-59-2(ethyl 5H,6H,7H-pyrazolo[3,2-b][1,3]oxazine-2-carboxylate)